+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 85Years
All Genders
ID05140148

Study of Amantadine to Help Recovery After Ischemic or Hemorrhagic Stroke in Adults Aged 18 to 85

Led by University of Pennsylvania · Updated on 2026-03-30

60

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether amantadine can help patients recover after ischemic or hemorrhagic stroke in this randomized, triple-blind clinical trial. The study is sponsored by the University of Pennsylvania and focuses on measuring stroke recovery and safety outcomes over a total enrollment period of three months. Participants will be randomly assigned to receive either amantadine or a placebo. Amantadine is given as 100 mg twice daily for those under 65 years old, or once daily for those 65 and older. The study drug or placebo is taken for one month, after which patients continue in the study for follow-up assessments. During the study, patients will undergo evaluations including questionnaires and neurological tests at various time points to track stroke recovery and monitor safety. Researchers will measure outcomes such as treatment-emergent adverse events, stroke impact scales, cognitive tests, limb strength, and functional scores up to 90 days post-treatment. Participation lasts three months in total, including the treatment and follow-up periods.

CONDITIONS

Brief Title

Promoting Recovery After STroke With Amantadine

Research Team

A

Aaron Rothstein, M.D

N

Nichole Gallatti, M.S.Ed.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here